**Name of Journal:** *World Journal of Transplantation*

**Manuscript NO:** 38695

**Manuscript Type:** REVIEW

**Thrombotic microangiopathy after renal transplantation: Current insights in *de novo* and recurrent disease**

Abbas F *et al*. TMA after renal transplantation

Fedaey Abbas, Mohsen El Kossi, Jon Jin Kim, Ajay Sharma, Ahmed Halawa

**Fedaey Abbas,** Nephrology Department,Jaber El Ahmed Military Hospital, Safat 13005, Kuwait

**Fedaey Abbas,Mohsen El Kossi, Jon Jin Kim, Ajay Sharma,Ahmed Halawa,**Faculty of Health and Science, University of Liverpool, Institute of Learning and Teaching, School of Medicine, Liverpool L69 3GB, United Kingdom

**Mohsen El Kossi,** Doncaster Renal Unit, Doncaster Royal Infirmary, Doncaster DN2 5LT, United Kingdom

**Jon Jin Kim,** Nottingham Children Hospital, Nottingham NG7 2UH, United Kingdom

**Ajay Sharma,** Tranasplant Surgery, Royal Liverpool University Hospitals, Liverpool UK L7 8XP, United Kingdom

**Ahmed Halawa,** Department of Transplantation Surgery, Sheffield Teaching Hospitals, Sheffield S57AU, United Kingdom

**ORCID number:** Fedaey Abbas ([0000-0001-8673-4344](http://orcid.org/0000-0001-8673-4344)); Mohsen El Kossi ([0000-0002-2490-2784](http://orcid.org/0000-0002-2490-2784)); Jon Jin Kim ([0000-0003-4307-8513](http://orcid.org/0000-0003-4307-8513)); Ajay Sharma (0000-0003-4050-6586); Ahmed Halawa ([0000-0002-7305-446X](http://orcid.org/0000-0002-7305-446X)).

**Author contributions:** Abbas F designed the study, data collection, writing the manuscript; El Kossi M, Kim JJ and Sharma A reviewed and edited the manuscript; Halawa A contributed to conceptualization, designing the study, supervising the data collection and reviewing and editing the manuscript.

**Conflict-of-interest statement:** No conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Ahmed Halawa, FRCS (Gen Surg), FRSC, MD, MSc, Senior Lecturer, Surgeon,** Department of Transplantation Surgery, Sheffield Teaching Hospitals, Herries Road, Sheffield S57AU, United Kingdom. [ahmed.halawa@sth.nhs.uk](mailto:Ahmed.Halawa@sth.nhs.uk)

**Telephone:** +44-77-87542128

**Fax:** +44-11-42714604

**Received:** March 10, 2018

**Peer-review started:** March 11, 2018

**First decision:** March 30, 2018

**Revised:** June 26, 2018

**Accepted:** July 9, 2018

**Article in press:**

**Published online:**

**Abstract**

Thrombotic microangiopathy (TMA) is one of the most devastating Sequalea of kidney transplantation. A number of published articles have covered either *de novo* or recurrent TMA in an isolated manner. We have, hereby, in this article endeavored to address both types of TMA in a comparative mode. We appreciate that *de novo* TMA is more common and its prognosis is poorer than recurrent TMA; the latter has genetic background, with mutations impact on disease behavior and, consequently, on allograft and patient survival. Post-transplant TMA can occur as a recurrence of the disease involved the native kidney or as *de novo* disease with no evidence of previous involvement before transplant. While the atypical hemolytic uremic syndrome is a rare disease that results from complement dysregulation with alternative pathway overactivity, *de novo* TMA is a heterogenous set of various etiologies and constitutes vast majority of post-transplant TMA. Management of both diseases varies from simple maneuvers, *e.g.*, plasmapheresis, drug withdrawal or dose modification to lifelong complement blockade that is rather costly. Careful donor selection and proper recipient preparation including complete genetic screening would be a pragmatic approach. Novel therapies, *e.g.*, purified products of the deficient genes, though promising in theory, are not yet of proven value.

**Key words:** Thrombotic microangiopathy; Kidney transplantation; *De novo* thrombotic microangiopathy; Recurrent thrombotic microangiopathy; Atypical hemolytic uremic syndrome

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Many articles in the literature have covered either *de novo* or recurrent thrombotic microangiopathy (TMA) in an isolated manner, we tried here in this article to gather the criteria of both types in one review for comparison. In contrary to what was believed in the past, *de novo* TMA is more common and its prognosis is poorer. On the other hand, recurrent TMA relies on a wide base of genetic background, with mutation errors differ in their impact on disease behavior and consequently on allograft and patient survival. This base for instance is rapidly expanding, that ultimately warrant a parallel robust work up regimen.

Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in *de novo* and recurrent disease. *World J Transplant* 2018; In press

**INTRODUCTION**

Thrombotic microangiopathy (TMA) is a debilitating complication of kidney transplantation that is associated with poor patient and graft outcomes. The incidence of post-transplant TMA has been reported to be 5.6 cases per 1000 renal transplant recipients per year with a 50% mortality rate at 3 years after diagnosis[1]. TMA after transplantation can be classified into either: (1) *De novo* TMA, *i.e.*, developed for the first time without any evidence of the disease before transplant; and (2) Recurrent TMA, *i.e.*, native kidneys failed as a result of TMA and it came back in renal transplantation. Since renal biopsy of native kidney is not performed in many patients with end stage renal disease (ESRD), missed diagnosis of TMA prior to kidney transplantation is likely. With the advent of drug eculizumab, an anti C5 monoclonal antibody, that is highly effective in prevention as well as treatment of atypical hemolytic uremic syndrome (aHUS), it would be crucial to know the etiology of ESRD in order to differentiate *de novo* from recurrence. Such distinction will invariably have clear clinical and therapeutic implications. In this review, we shall try to discuss the main differences between the two categories in the pathophysiology, clinical course and available approaches of prevention and treatment.

***DE NOVO* TMA**

In the presence of acquired or genetic dysregulation of the alternative complement pathway (AP), a number of precipitating factors have been identified in the context of renal transplantation that trigger the development of *de novo* TMA. These factors include the following: (1) Antibody mediated rejection (AMR); (2) Immunosuppressive-associated TMA: CNI or mTOR inhibitors (mTORi), single or combined; (3) Other medications: *e.g.*, anti-vascular endothelial growth factor inhibitors (anti-VGFI); (4) Viral infection: *e.g*., HCV, CMV, BK and parvovirus; (5) Genetic abnormalities in the complement cascade; (6) Phenotypical shift of C3 glomerulopathy (with ESRD), to an aHUS post transplantation; and (7) Missed diagnosis of TMA in the native kidney as a cause of ESRD (*i.e*., recurrent TMA)[2].

***Which is more prevalent, de novo or recurrent TMA?***

Reynolds *et al*[1] (2003) in USRDS-based study, declared that the number of recurrent TMA cases was only 12 as compared to 112 patients with *de novo* TMA, though the risk of post-transplant TMA recurrence was 36.5 times higher in kidney transplant recipients with ESRD due to hemolytic uremic syndrome (HUS) as compared to other etiologies (29.2% *vs* 0.8%)[1]. Langer *et al*[3] reported the incidence of *de novo* TMA to be 1.5%. However, the incidence of *de novo* TMA is mentioned as high as 3%-14%[4,5]. It is clear that *de novo* TMA is more prevalent after kidney transplantation and presumably underestimated. Graft loss rate to the tune of 40% is reported in *de novo* TMA within a couple of years of diagnosis[5,6].

***Etiopathogenesis of de novo TMA***

AMR and medications are the two main causes of *de* *novo* TMA. In addition, the role of complement abnormalities is becoming more apparent with one study reported an underlying complement mutational abnormality in one third of patients with *de novo* TMA[7].

**Calcineurin-induced TMA:** The link between calcineurin (CNI) (CyA and tacrolimus) administration and the evolution of *de novo* TMA is not a new concept. Three underlying mechanisms could explain the role of CNI in TMA development: (1) Loss of the normal balance between the vasodilator peptides (*e.g*., prostaglandin (PG) E2 and prostacyclin (PG12)) and the vasoconstrictor peptides (*e.g*., thromboxane A2 and endothelin), results in arteriolar vasoconstriction[8,9], renal ischemia and establishment of endothelial injury[10]; (2) CNI-induced platelet activation, pro-coagulant and anti-fibrinolytic activity have been shown to be involved in TMA evolution, particularly so, with an injured endothelium due to AMR, ischemia-reperfusion injury or any other etiology[10-12]; and (3)Microparticles production from the endothelial cells, a known effect of CyA that can result in activation of the AP, a well-known mechanism that is implicated in TMA evolution[13]. However, three trap points have been speculated to oppose the role of CNI: (1) Patients utilizing CNI to maintain immunosuppression represent more than 95% of kidney transplant recipients (KTR), only a small percentage can develop TMA, which suggests the presence of another underlying predisposing factor (s)[14]; (2) CNI withdrawal in *de novo* TMA does not always guarantee a favorable graft outcome[6]; (3) An United States Renal Data System (USRDS)-based study demonstrates a significantly higher incidence of TMA in the group of KTR that was not under CNI maintenance therapy (11.9/1000/year), as compared to those on CNI maintenance (5.0/1000/year)[1].

**mTOR inhibitors-associated TMA:** ThemTOR inhibitors (mTORi) can inhibits cell cycle progression and proliferation. Both sirolimus and everolimus have been reported to be implicated in the pathogenesis of *de novo* TMA. The following explanations have been given: (1) mTORi have antiangiogenic properties, and can decrease renal expression of the vascular endothelial growth factor (VEGF) with death of the endothelial progenitor cells. These effects are proved to be implicated in TMA pathogenesis[15,16]; (2) The VEGF inhibition is proved recently to be associated with reduced renal level of complement factor H (CFH)[17]. Patients with underlying CFH genetic mutations are more susceptible to develop *de novo* TMA, particularly with mTORi exposure[7]; (3) Repair of endothelial injury could be hampered by mTORi use[18-20]; and (4) Furthermore, the procoagulant and the antifibrinolytic activity of mTORi might play additional role in *de novo* TMA development[21,22].

The exact role of mTORi in evolution of *de novo* TMA is not fully understood[3,18,23]. Some authors suggested that the impact of these medications may exceed that of CNI in development of *de novo* TMA[1,24]. However, interpretation of these data may be limited by the fact that mTORi itself, *e.g.*, sirolimus may be used as a rescue medication in case of diagnosis of CNI-induced TMA[1,24]. The risk of development of TMA with combined CNI and mTORi protocols is higher than using mTORi alone, an effect that has been documented in several studies. While Fortin *et al*[18], reported that the highest risk of *de novo* TMA was in the group using CNI and mTORi, Nava *et al*[20], studied 396 KTR, 36 (7.3%) developed TMA and 17 of them were drug-related. Not only were the drug levels of CNI and mTORi higher in the TMA group, but also the sum of both drug levels in the TMA group was also higher[18-20]. An explanation for this additive risk is that the repair of the endothelial injury induced by the CNI is hampered by mTORi[18-20]. Therefore, immunosuppression protocols using drug combinations should be planned cautiously, when high doses of these agents are usually used as in early post-transplant period[7].

**AMR-associated *de novo* TMA:** The role of AMR in development of post-transplant TMA is commonly reported and well-recognized[1]. Endothelial cell is a well-known target of allo-immune response. The peritubular capillaries (PTC) C4d staining (a well-recognized surrogate marker of AMR) have been reported to be present in 16.2% of biopsied recipients with TMA[1,25]. Moreover, Satoskar *et al*[6], reported incidence of 55% of *de novo* TMA patients who express diffuse PTC C4d positivity. The observed prevalent administration of CyA in this study argued that it may have an augmenting effect on TMA prevalence. However, the observed difference between TMA in patients with C4d positive biopsy (13.6%) and that in C4d negative biopsies (3.6%) favors a postulated role of the humoral rejection in the evolution of post-transplant TMA[2]. Both studies, for instance, demonstrated that clustering of both AMR and TMA would predict much worse graft outcome[6,26].

**Other causes:** Several less common etiologies have been reported to be involved in TMA pathogenesis include: Viral infection, *e.g.*, CMV infection[27,28], BK virus[29], parvovirus[30,31], chronic hepatitis C virus (with or without anti-cardiolipin seropositivity)[32,33], antiviral medications, *e.g*., ribavirin and interferon[34] and disseminated histoplasmosis[35,36]. Ischemia-reperfusion injury can augment complement-associated injury through complement activation[37]. An acquired disintegrin and [metalloproteinase](http://www.sciencedirect.com/topics/medicine-and-dentistry/metalloproteinase) with a [thrombospondin](http://www.sciencedirect.com/topics/medicine-and-dentistry/thrombospondin) type 1 motif, member 13 (ADAMTS13) deficiency-another rare risk factor- has been shown in a case to represent as a post-transplant TMA[38,39]. Unfortunately, the role of rare risk factors is rather difficult to evaluate in controlled studies. Living donation, on the other hand, has not proved to guarantee any protection against graft dysfunction[5]. Interestingly, a C3 glomerulopathy disease in a native kidney can undergo phenotypical shift and present after kidney transplantation as *de novo* TMA[40].

**Complement gene mutations:** Chua *et al*[41] (2015) reported that renal complement activation is the common denominator in such a heterogeneous condition. They observed C4d deposits in more than 88% and C4d with localized C5b-9 in about 60% of 42 biopsy samples from patient with histologically confirmed diagnosis of TMA from a heterogenous group of patients[41]. Moreover, Le Quintrec *et al*[7], reported the presence of genetic mutations in CFH, CFI or both in 29% of their studied *de novo* TMA patients, 25% showed low F.B and/or low C3, suggesting an AP complement activation. No mutations have been found in healthy controls (100) or in TMA-free KTR controls[7].

**Relation to TMA evolution:** The AP depends on two main regulators: CFH and complement factor I (CFI). CFH has the ability to dissemble C3 cleaving enzyme C3bBb. Moreover, it can serve as co-factor for FI, the latter has the ability to inactivate C3b. Consequently, inactivation of these proteins either due to genetic mutations or development of neutralizing antibodies can trigger an uncontrolled AP activity leading to endothelial injury, the pathogenetic base of TMA. Interpreting the results of the above study may suggest an overlap between aHUS and TMA. However, multiple mutational gene varieties related to complement and the coagulation-fibrinolysis cascades have been recently recognized in TMA patients[42].

***Clinical manifestations***

**Timing**: TMA could develop at any time in the post transplantation course[5,43], however, this syndrome is mostly encountered at the first 3-6 mo post transplantation. This is probably when the CNI immunosuppressive trough levels are relatively higher[1].

**Salient features:** TMA manifestations are quite variable and can vary from a limited form confined to the kidney to a full blown systemic variant[4,6,44]. The systemic form of TMA consists of the classic triad of thrombocytopenia, microangiopathic hemolytic anemia (MAHA) and acute kidney injury (AKI). Features of MAHA include raised LDH, drop in HB and decreased [haptoglobin](http://www.sciencedirect.com/topics/medicine-and-dentistry/haptoglobin) with schistocytes on peripheral blood smear. Localized (limited) TMA is usually presented later in TMA course, as compared to systemic form, which can be explained by the urgency of the systemic type, necessitating the diagnostic allograft biopsy[4]. When a renal transplant recipient has significant renal dysfunction and the biopsy does not show any acute rejection, one must suspect 2 possibilities: (1) TMA; or (2) Renal artery stenosis. The histopathologic changes are usually non-specific, but vary in the acute status to the chronic angiopathic changes. In the active stage, there is evidence of endothelial cell injury with platelet aggregation (thrombosis), fibrinoid necrosis and glomerular ischemia. In the chronic stage, duplication and multilayering of the basement membranes with increased matrix layers and vessel wall cells that ultimately end in the unique onion skin formation (Figure 1)[2,45].

Once the diagnosis of TMA has been established, a prompt revision of the etiology of the native kidney ESRD should be instituted. In aHUS patients who do not show systemic manifestations, the diagnosis could be obscure. In absence of renal biopsy, many cases can be misdiagnosed as hypertensive nephrosclerosis[2]. Consequently, a prompt testing for genetic mutations should be accomplished to unmask an underlying complement dysregulation and avoid missing the diagnosis of a recurrent aHUS. This approach has key therapeutic implications, since *de novo* TMA has limited therapeutic options, in contrast to recurrent aHUS after transplantation, which has a better chance of C-5 blockade through the monoclonal antibody, eculizumab, an effective therapeutic agent not only for treatment, but also for prevention of recurrence[2,46].

**Prognosis of *de novo* TMA:** The prognosis of post-transplant *de novo* TMA is quite poor for patient and as well as allograft. About one half of the patients loses their graft within the first two years after diagnosis[4,6]. This is supported by the USRDS-based report presented by Reynolds *et al*[1], that showed patients mortality rate of 50% after 3 years of diagnosis. Many studies support these results[4-6,18]. To compare systemic versus localized TMA, Schwimmer *et al*[4] reported that 54% of systemic TMA develops dialysis-requiring AKI and 38% lost their grafts. On the other hand, no one patient of the localized TMA developed TMA-related early graft loss or required dialysis. Unfortunately, this variation in both types behavior has not been reflected on graft survival, both types of TMA face poor long-term graft survival[2,4].

**RECURRENT TMA AFTER RENAL TRANSPLANTATION**

***Etiology of the recurrent TMA***

aHUS; thrombotic thrombocytopenic purpura (TTP); and autoimmune diseases: *E.g.*, scleroderma and systemic lupus erythematosus, with or without anti-phospholipid antibody syndrome[2].

**aHUS:** Recurrence of TMA in the allograft depends on the underlying type involved the native kidney. Overactivation of the AP is known to be the underlying etiology of the aHUS. By far aHUS is the commonest diagnosis in TMA associated with recurrence. Risk of recurrence is greatly dependent on the underlying associated abnormality[47]. For example mutational abnormality involving CFH and CFI, regulatory complements component produced by the liver, results in aberrant CFH and CFI. After transplant, CFH and CFI have a robust impact in evolution of aHUS recurrence. The reported rate of aHUS recurrence approached 70%-90%[47,48]. Membrane co-factor protein (MCP), a transmembrane complement regulatory component that is produced by kidney endothelial cells even in post-transplant period, keeps aHUS recurrence lower unless another mutational gene defects have been associated[47-49]. Additional MCP mutations (> 22%), as reported by Bresin *et al*[50], led to graft loss due to recurrence of aHUS in one third of patients. The global rate of recurrence in aHUS patients is reported to be as high as 60%. Untreated patient, however, ultimately develop graft loss rate of 90%, with 80% of them occur in the first year[50].

**TTP:** TTP is the second recognized etiology in TMA. Genetic or acquired lack of ADAMTS13 has been recognized. For a long period, differentiation between TTP and HUS relied primarily on the presence of neurologic manifestation in TTP and renal dysfunction in HUS to settle the diagnosis. Serological evaluation of ADAMTS13 activity is now feasible. However, complete distinction between the two clinical entities is not always possible because of overlap in manifestations. Recently, Zafrani *et al*[51], documented the presence of AKI in more than half of TTP patients (with low ADAMTS13 activity) and 50% progression of CKD and even ESRD. It is reasonable to expect TTP recurrence as long as the underlying defect is present after transplantation[52]. The same explanation can be applied to the autoimmune diseases, *e.g*., lupus nephritis, wherein patients can develop TMA in 5%-10% with documented recurrence after kidney transplantation[53-57].

## Pathology: aHUS is a variety of TMA that represents the tissue response to an ongoing endothelial injury. Thrombotic features, *e.g*., fibrin/platelet plugging and intraluminal fibrin are not always be seen in renal allograft biopsy. Non-thrombotic features can appear as denuded and swollen endothelium, mesangiolysis, glomerular basement membrane double contour as well as accumulation of electro lucent material in the subendothelium. Arterial and arteriolar intraluminal fibrin, myxoid intimal thickening as well as concentric myointimal proliferation (onion skin appearance) have been also described[58] (Table 1).

**PATHOPHYSIOLOGY OF TMA RECURRENCE**

The AP is constitutively active and is, therefore, fine-tuned. The regulatory components exist either in the serum (fluid phase) or attached onto cell membranes. CFH is the main inhibitor of the AP. CFH has the ability to work in fluid phase as well as on cell surfaces. Furthermore, CFH can act as a co-factor to CFI[59,60]. Regulatory components on cell surfaces, or “membrane regulators” include the following: (1) Membrane cofactor protein (MCP/CD46); (2) Complement receptor 1 (CR1/CD35); (3) Decay accelerating factor (DAF/CD55); and (4) Protectin (CD59), that prohibits MAC formation[61,62].

Any disturbance involving any of this protective shield will ultimately lead to complement activation with subsequent endothelial cell derangement[63]. It is increasingly recognized that complement dysregulation is the fundamental etiology involved in TMA evolution. Both genetic aberrations as well as autoantibodies can be involved in this process. Usually, there is (are) an inciting environmental trigger factor(s).

***Current classification of TMA include the following***

**Primary hereditary TMA:** That includes mutations in ADAMTS13, MMACHC (cb1c deficiency), or with genes encoding complement components.

**Primary acquired TMA:** Autoantibodies to ADAMTS13, or to CFH, that occurs with homozygous CFHR3/1 deletion.

**Infection-associated TMA:** Shiga toxin–producing Escherichia coli-HUS (STEC-HUS) and pneumococcal HUS have distinct mechanisms result in TMA; in other infections, the processes are ill-defined and sometimes can trigger manifestations of the primary TMA.

**Secondary TMA:** Presents in a variety of conditions, and in many conditions the culprit mechanisms are usually multifactorial or unknown. The shown classification (Figure 2) is not unequivocal, *i.e.*, in some secondary forms of TMA, *e.g*., pregnancy-associated TMA or *de novo* TMA after transplantation, a significant percentage of cases may be associated with genetic predisposition (Figure 2)[64].

The most common complement mutation in aHUS is CFH, with 40% of cases inherited and 25% sporadic[65,66]. Furthermore, not only CFH has its impact on TMA evolution, but also its family, the CFH-related genes (CFHR1-5) has an additional role. Through deletion, hybrid proteins formation and duplications[67] of these genes, endothelial cell surface became denuded from its protective shield, consequently aHUS may supervene[65,68].

The risk of aHUS recurrence could be four times higher with CFH mutations or with the carriers of hybrid gene between CFH/CFHR1[24]. On the other hand, the impact of CFI mutations is controversial. While the early reports about CFI mutations documented a high rate of recurrence and graft loss[69-71], Bienaimé[72] *et al* denied any risk associated recurrence with CFI mutations. Le Quintrec *et al*were in agreement with them[24]. As MCP can be normally expressed by the endothelial cell surface of the allograft, aHUS recurrence is seldom influenced by MCP gene mutations. No more than three cases of MCP-associated recurrence have been reported[73,74], where recurrence was attributed either to combined gene mutations[49] or microchimerism related to the recipient’s endothelium[74] (Table 2).

There is paucity of data on the role of thrombomodulin (THBD) gene mutations in aHUS. Like MCP, THBD is membrane-anchored, so the possibility of recurrence is rarely seen. Only few cases have been reported[75,76]. Gain of function mutation (C3 and CFB) is vulnerable for recurrence. Recurrent aHUS with subsequent graft loss have been reported in up to four cases of CFB carriers[77,78]. On the other hand data related to C3-asociated recurrence are conflicting. While Le Quintrec *et al* documented recurrence in four of five allografts[24], Noris *et al*[79] reported only two cases out of seven transplant with *C3* mutations. Zuber *et al*[80] postulated that is that normal C3 supplied by the graft tissues might have a protective effect.

**Role of diacylglycerol kinase-ε (*DGKE*) mutations:** Until recently, the vast majority of aHUS patients were thought to be associated with AP dysregulation. On contrary, most patients with *DGKE* mutations exhibit no evidence of complement overactivity. The homozygous mutations in gene encoding for DGKε and DGKε-associated nephropathy have been recently uncovered. Complete loss of function is associated with acute renal failure, thrombocytopenia and hemolytic anemia. Consequently, it has been postulated that DGKε protein may play a fundamental role in regulating thrombosis in renal tissues, a robust fact that urged expert renal clinicians to include DGKE mutations in the pathophysiology of aHUS[81,82] (see treatment below).

**Environmental triggers:** The process of aHUS recurrence can be triggered by anti-HLA antibodies[6], viral infection, ischemia-reperfusion injury and immunosuppressive medications[83], either isolated or in clusters can initiate the cascade of complement activation in susceptible patients.

## Clinical assessment of aHUS: Any HUS that is not due to STEC-HUS, has been called aHUS[75]. The recent progress in understanding the pathophysiology and the underlying genetic factors lead to the current classification of aHUS[84]. Consequently, the term “primary HUS” has been addressed by some clinicians when there is underlying abnormality in the AP. However, patients with underlying complement abnormality, need trigger factor, *e.g*., infection, including pneumococcal infection (T-antigen associated TMA), surgery, medications, pregnancy, so that aHUS can be clinically manifest[85,86].

***Acute vs chronic lesion?***

Timing of an aHUS episode is not easily predictable. Many patients are at persistent risk of recurrence. In [medical genetics](https://en.wikipedia.org/wiki/Medical_genetics), penetrance of any disease-causing mutation means the percentage of subjects with genetic mutations who can express clinical symptoms[87]. Penetrance in aHUS is age-related, by the 70th of age, penetrance reaches 64%[88], which supports the presence of disease modifier by the aging process. The fact that certain patients (3%-5%) may express more than one genetic variant, supports the postulation that mutation burden determines the magnitude of disease penetrance. The late presentation of aHUS reflects the impact of the environmental triggers. However, dissociation between the pathological entities and the clinical presentation have been reported. For example, TMA can be diagnosed in tissue biopsy without simultaneous decline in platelet count. Moreover, the current use of eculizumab has its impact on the natural history of aHUS[89]. Complement inhibition can improve glomerular perfusion enough to maintain kidney function. Once this biological agent withdrawn, renal endothelium may interact with the complement system through an unknown mechanism. More studies are obviously warranted to declare these alterations[58].

### Extrarenal renal manifestation: Twenty percent of aHUS patients can express extrarenal manifestations in the form of: Digital gangrene, cerebral artery thrombosis, myocardial infarction, in addition to ocular, GIT, pulmonary and neurologic involvement[42,90-98]. Drusen formation is not common in aHUS[99].

### Laboratory investigations and differential diagnosis: Once the diagnosis of aHUS is suspected, exclusion of ADAMTS13 activity is urgently mandated to exclude TTP diagnosis. In children, TTP is less common; therefore, eculizumab therapy should be instituted early without waiting the results of ADAMTS13 activity. In addition, 5% of STEC-HUS patients have no prodromal diarrhea and 30% of complement-mediated aHUS patients can present with a diarrheal prodrome[100].

### Complement assessment in aHUS: Before commencing plasma therapy, serum complement component should be thoroughly evaluated. C3 is low in 30% of aHUS patients and, therefore, cannot be used as a screening criteria for aHUS[97,101]. CD 46 surface expression should be assessed by the flow cytometry. Functional parameters as well as activation markers should be also determined. Whether these biological markers can be used to guide therapy requires further investigations[102] (Table 3).

### Panel of genetic testing: The diagnostic list of genes of aHUS should include at least: CFH, CFI, C3, CFB, THBD, CFHR1, CFHR5 and DGKE[48,65,75,103-105]. Genotyping workup should also include CFH-H3 and MCP ggaac haplotypes[106]. Recent advances in genetic surveys addressed the use of copy number variation (CNV), hybrid genes, and the complex genomic rearrangements of CFH/CFHRs genomic region[68,107-111]. The full-detailed genetic mapping, however, allows proper diagnosis and therapeutic plans, and helps in genetic counselling, particularly in living related-donation[112]. The role of living-related kidney donor transplantation in aHUS is that the culprit agent(s), either acquired or genetic, should be well-recognized, and the donor should be free of this factor (s) at the same time. Consequently, the presence of *CFH* or *MCP* mutations in the donor is not-per se- a contraindication for donation[58].

## Rational for genetic screening: The current progress in understanding the underlying genetic background of aHUS and its molecular basis, makes it paramount to provide a full detailed genetic map before transplant, the following explanations have been given: (1) Determination of the actual cause of the disease that allow correct genetic counseling; (2) Drawing the plan of disease management; (3) Evaluating the expected response for therapy; (4) Defining the prognostic course as well, as patient and allograft survival; and (5) These studies, however, did not hamper the progress in clinical diagnosis and therapy institution before irreversible Sequalea have been established[113]. A schematic presentation for the “genetic drivers” of aHUS is supplied in Figure 3[58].

**Interpretation of the genetic variants:** Genetic mutations can be interpreted as: (1) Benign; (2) Likely benign; (3) Variant of uncertain significance; (4) Likely pathogenic; or (5) Pathogenic, according to the international guidelines[114].

The pathogenic mutations in aHUS have the ability to hamper the capacity to protect the endothelial lining and the platelet from the devastating effect of complement or its activation[78,115-121]. It is well-documented now that pathogenic variant combinations as well as clustering of risk factors facilitate the evolution of aHUS[49,88,122-125]. Genetic designation has also its impact on therapeutic plans, response to therapy as well as the chance for aHUS recurrence[79,126] (Table 4).

## Acquired drivers of aHUS: The FH autoantibodies are the best reported example. It is typically characterized by homozygosity for delCFHR3-CFHR1. Test results need to be confirmed after two weeks, if the initial results were positive. According to the consensus guidelines in pediatrics, CFH autoantibodies assessment should be confirmed, if positive, on a regular basis[84]. About quarter of patients with anti-CFH–associated HUS are vulnerable for relapse.

**Diagnosis of aHUS recurrence:** A full detailed clinical history is usually warranted. A proven tissue diagnosis with LM, IF and EM studies supporting the diagnosis of aHUS in the native kidney should be available. However, once diagnosis of aHUS is suspected, a full battery of biochemical, genetic as well as pathological investigations of the AP should be accomplished[127], including the following: (1) Estimation of the anti-CFH AB; (2) MCP screening on the peripheral blood WBCs; (3) Examination of the recombination in CFHR region; and (4) Screening of the genetic mutations related to CFH, CFI, CFB, C3, and MCP.

The impact of various genetic mutations on allograft survival is not universally quantifiable. Not all the genetic mutations share the same magnitude of risk on allograft survival. Despite the fact that genetic screening is difficult and complex and the spectrum of gene mutation is a continuously expanding field[102], performing such studies is fundamental to determine the possible outcome of the kidney transplant in the set of aHUS recurrence[128].

**THERAPY OF POST-TRANSPLANT TMA**

***Treatment of de novo TMA***

In view of the extreme heterogenicity of the mechanisms related to variable etiologies of TMA, therapeutic maneuvers should be individualized for each patient. Institution of therapeutic options is highly dependent on diagnosis as well as patient’s response. The following approaches has been suggested: (1) Immunosuppressive medications management: the role of immunosuppressive medications (*e.g.,* CNI or mTORi) has been reported in the literature, with a documented better response after switching from one CNI member to another or to an mTORi)[5,129-134]. However, this was not agreed by Satoskar *et al*[6], who denied any difference in outcomes between temporary discontinuation, dose modulation, withdrawal or continuation of CyA in management of *de novo* TMA. Whatever the situation would be, the withdrawal of the offending agent should be the first line in treating *de novo* TMA, a fundamental step that ultimately results in correction of the hematological profile[2]; (2) Plasmapheresis (PE) and intravenous immunoglobulins (IVIG): The following rationales have been addressed in favor of PE/IVIG therapy: Depending on its efficacy in treating patients with TTP[135,136], and previous choice as a first line therapy for aHUS (replaced now by eculizumab), PE with IVIG has been extrapolated to be early used in treating *de novo* TMA patients. In 2003, Karthikeyan *et al*[43], reported a graft salvage rate with PE approaching 80%. Two benefits have been postulated for this type of therapy: Removal of the platelet aggregation factors, *e.g*., [thromboxane](http://www.sciencedirect.com/topics/medicine-and-dentistry/thromboxane) A2; Simultaneous replenishment of the deficient factors, *e.g.*, PGI2-stimulating factor[43]; With the possibility of presence of underlying complement dysregulation in patients undergoing kidney transplantation due to systemic TMA[7], in the same manner, it is reasonable to speculate that PE can be beneficial for two reasons: Removal of the abnormal mutant complement proteins; Supplying normally functioning complement components[7]; In the AMR-associated TMA, an improved outcome has been reported which was attributed to removal of the anti-HLA antibodies[6,137]; A 100% response has been reported to be associated with PE/IVIG therapy in 5 solid organ transplantation with systemic TMA with no evidence of relapse after withdrawal of the culprit agent (*e.g*., tacrolimus) in a recent study[2]; (3) Belatacept: A promising alternate option that allows withdrawal of the offending drug incriminated in TMA evolution. Belatacept is an immunosuppressive co-stimulatory blocker against CD80 and CD86 surface ligands and CD28 on T cells. The first case report, in 2009, documented TMA resolution after belatacept therapy used for immunosuppression in post transplantation TMA due to CNI-induced endothelial toxicity[138]. Two case series have been followed thereafter documenting fair graft outcome due to resolution of the CNI-induced TMA[139,140]. Of note, belatacept has nothing to do with the underlying endothelial derangement, its role is only to replace/ displace the culprit drug[2]; and (4) Complement inhibition: Eculizumab, an anti-C5 agent, blocks the lytic C5b-9 membrane attack complex generation. This recombinant monoclonal antibody addressed a breakthrough in the management of aHUS, as it was proved to be effective in treatment as well as in prevention of the recurrent aHUS after renal transplantation[141]. A large percentage of patients with diagnosed TMA express complement activation, including those patients with unrecognized complement genes[2]. For example, Chua *et al*[42] reported C4d renal deposition in all histologically documented cases with post transplantation TMA. These data delineate that complement overactivation can be considered as one of the final common pathways incriminated in TMA evolution[2]. Consequently, anti-complement therapy has been suggested to have a fundamental role in the management of *de novo* post-transplantation TMA. Efficacy of eculizumab has been documented in several case reports and case series in management of resistant cases of medication-associated TMA, including cases with unrecognized genetic defects[142-147]. This efficacy has been also documented in patients with refractory AMR with TMA[147-156].

On the other hand, Cornell *et al*[157] reported no deference in death-censored graft survival or biopsy finding at one year, when they compared the outcome of eculizumab treated patients with positive cross matching with controls, despite that the incidence of acute AMR was less in eculizumab group. So, in view of these conflicting results as well as considering the high cost of the drug, the use of this vital biological agent should be confined to a specified subset of *de novo* TMA patients, presumably: (1) AMR-associated TMA; (2) Patients became PE-dependent; and (3) Refractory hemolysis persists despite maximum doses of PE therapy. However, more efforts still warranted declaring the best way to utilize this unique agent and which subset of TMA patients are the best candidate for this costly drug. An urgent need for new biomarkers is also warranted for early detection of complement over activity[2] (see kidney transplantation without eculizumab prophylaxis below).

***Treatment of the recurrent TMA***

**Recommendations for recurrent TMA:** First of all, it is worthy to remind that most of the recommendations about recurrence and therapeutic advices relied primarily on case reports (level 4 evidence) as well as experts’ opinions (level 5 evidence) rather than on randomized controlled trials (level 1b evidence): (1) The minimal list of genetic screening should include: CFH, CFI, CFHR, CFB, MCP and C3[158]; (2) All patients with primary or suspected aHUS, should be surveyed for all complement components and its related proteins; (3) Patients with isolated MCP associated mutations (not combined with other mutations) may be safe for kidney donation; (4) Patients with documented aHUS and with lack of definite genetic mutations can proceed in renal transplantation under umbrella of intensive plasma exchange therapy[159]; and (5) Polygenic pattern for aHUS patients should be handled with extreme caution in case of living donation[80].

**Prevention of aHUS:** The following strategies are suggested to decrease/prevent aHUS: Complement activity incited by an injury to endothelium, *e.g.*, ischemia-reperfusion injury, viral infection and immunosuppressive medications[127], should be avoided; (2) Certain relation has been reported between CNIs use and aHUS recurrence[160] which is not confirmed by other authors[15,112], even the usual substitute in such a case (an mTOR) is not innocent and can induce recurrence[15,112]; (3) We cannot depend solely on PE therapy in management of aHUS recurrence for several reasons: PE failed to prevent aHUS recurrence in many cases[161]; PE cannot guarantee prevention of aHUS recurrence after cessation of therapy; Many cases under PE therapy were proved to develop “subclinical” aHUS recurrence, which means that PE therapy cannot influence complement activity; Prophylactic use of rituximab proved to be efficacious as anti-CFH-antibodies[162], the beneficial effect of rituximab can be enhanced by adding PE therapy[163,164]; and (4) The anti-C5 monoclonal antibiotic eculizumab has been reported to be used successfully to prevent aHUS recurrence in patients with CFH, CFH/CFHR1 hybrid genes as well as with C3 gene mutations[165-168] (see below).

**Prophylactic complement blockade:** Gene abnormalities have been reported to be associated with aHUS recurrence in 80% of patients[112]. In light of a robust evidence of increased complement activity during aHUS episodes[169,170] after exposure to a trigger, *e.g*., surgery or infection, clinical indication of complement blockade is suggested[171]. However, this explanation lacks enough evidence (Figure 4[58]).

## Therapeutic protocols for aHUS recurrence: Once the diagnosis of primary aHUS has been established, complement blockade therapy should be instituted. The available data points to two strategies: (1) Minimal dosage to establish complement blockade; and (2) Dose withdrawal scheme[142]. Both options, however, lack enough evidence and require precise monitoring of complement blockade (Table 5).

## FH autoantibody-driven aHUS: Anti-cellular therapy is recommended, with close monitoring of the antibody titer (Figure 5). How to monitor complement blockade? Detailed description is shown in Table 6.

**Duration of therapy:** There is not enough data supporting life-long therapy for aHUS. Cessation of therapy appears to be plausible in certain situations (Figure 6). An enough time, however, should be permitted to optimize renal recovery and satisfy TMA resolution. Early biomarkers of disease relapse due to complement activation or endothelial derangement as well as their inciting triggers should be thoroughly investigated in the future.

**Unanswered questions:** There is paucity of information about this biological agent, *e.g.,* what is the most optimal dose? What are the ideal dose-intervals? For how long this kind of costly therapy should be continued?[175] what impact of this agent on the spectrum of renal transplantation[113]?

**Cessation of therapy:** The following scheme is suggested for withdrawal of complement blockade therapy (Figure 6).

**Kidney transplantation without eculizumab prophylaxis:** A case series presented by [Verhave](https://www.ncbi.nlm.nih.gov/pubmed/?term=Verhave%20JC%5BAuthor%5D&cauthor=true&cauthor_uid=24038559) *et al*[179] (2013), described successful kidney transplantation without recurrence in four high risk aHUS patients. They received living donor kidney with therapeutic protocol consisted of: Basiliximab for induction, tacrolimus in low dose, and prednisone and mycophenolate mofetil as immunosuppressive in addition to a statin. Additional precautions include lowering the blood pressure and minimizing the cold ischemic time. No recurrence or rejection has been observed after 16-21 mo. This case series heralds the possibility of successful kidney transplantation in recurrent aHUS without the need for prophylactic eculizumab through minimizing cold ischemic time, decreasing the risk of rejection and, thereby, providing endothelial protection[179].

**Treatment of DGKE mutation associated TMA:** The role complement blockade here is questionable. Many cases experienced disease remission with no specific therapy. Azukaitis[82] and his colleagues reported the feasibility of kidney transplantation in 5 patients with no recurrence after transplantation.

#### RENAL TRANSPLANTATION

#### Timing

#### Renal transplantation should be postponed six months after institution of dialysis, as limited kidney recovery can occur several months after commencing eculizumab therapy[170,180]. Disappearance of the extrarenal manifestations as well as resolution of TMA hematological parameters are the prerequisite for kidney transplantation. The magnitude of risk of recurrence can be utilized to guide the necessity of anti-complement blockade (Table 2).

***Risk of Kidney donation***

Two risks have been reported to be associated with living-related kidney donation: (1) Recurrent disease in the recipient; and (2) *De novo* disease in the donor, if he/she is a genetic mutation carrier[169]. Any potential donor proved to exhibit alternative pathway dysregulation should be excluded. On the other hand, any potential living-related donor devoid of complement genes abnormality can be permitted[113]. “Liver transplantation” may be reserved for patients with liver-derived complement proteins aberrations, particularly in patients poorly responding to complement blockade[181].

***Future therapy***

The following future therapeutic agents have been addressed: (1) Purified products of the deficient genes; and (2) C3 convertase inhibitors[182].

***Research targets***

The following agents under investigation: (1) The anti-C3b blocker, compstatin analog Cp40[183]; and (2) The anti-C3 convertase monoclonal antibodies[184].

**CONCLUSION**

The impact of TMA, either *de novo* or recurrent, on allograft longevity is underestimated. The spectrum of the culprit genes implicated in the evolution of TMA is currently expanding. Despite the landmark breakthrough of immense efficacy of complement blockade therapy, the outlook of this devastating syndrome remains poor if the diagnosis is delayed. In contrast, the recurrent TMA is much more optimistic if there is timely intervention by complement blockade before permanent damage sets in. More efforts targeting genetic mutations management as well as the advent of early predictors of TMA recurrence are warranted for better disease control and, thereby, better patient and allograft outcome.

**REFERENCES**

1 **Reynolds JC**, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. *Am J Kidney Dis* 2003; **42**: 1058-1068 [PMID: 14582050 DOI: 10.1016/j.ajkd.2003.07.008]

2 **Garg N**, Rennke HG, Pavlakis M, Zandi-Nejad K. De novo thrombotic microangiopathy after kidney transplantation. *Transplant Rev* (Orlando) 2018; **32**: 58-68 [PMID: 29157988 DOI: 10.1016/j.trre.2017.10.001]

3 **Langer RM**, Van Buren CT, Katz SM, Kahan BD. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. *Transplantation* 2002; **73**: 756-760 [PMID: 11907423 DOI: 10.1097/00007890-200203150-00017]

4 **Schwimmer J**, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. *Am J Kidney Dis* 2003; **41**: 471-479 [PMID: 12552512 DOI: 10.1053/ajkd.2003.50058]

5 **Zarifian A**, Meleg-Smith S, O'donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. *Kidney Int* 1999; **55**: 2457-2466 [PMID: 10354295 DOI: 10.1046/j.1523-1755.1999.00492.x]

6 **Satoskar AA**, Pelletier R, Adams P, Nadasdy GM, Brodsky S, Pesavento T, Henry M, Nadasdy T. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. *Am J Transplant* 2010; **10**: 1804-1811 [PMID: 20659088 DOI: 10.1111/j.1600-6143.2010.03178.x]

7 **Le Quintrec M**, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, Fakhouri F, Provost F, Fridman WH, Thervet E, Legendre C, Zuber J, Frémeaux-Bacchi V. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. *Am J Transplant* 2008; **8**: 1694-1701 [PMID: 18557729 DOI: 10.1111/j.1600-6143.2008.02297.x]

8 **Remuzzi G**, Bertani T. Renal vascular and thrombotic effects of cyclosporine. *Am J Kidney Dis* 1989; **13**: 261-272 [PMID: 2650537 DOI: 10.1016/S0272-6386(89)80032-0]

9 **Ramírez C**, Olmo A, O'Valle F, Masseroli M, Aguilar M, Gómez-Morales M, Revelles F, García-Chicano MJ, Arrebola F, Reguero ME, del Moral RG. Role of intrarenal endothelin 1, endothelin 3, and angiotensin II expression in chronic cyclosporin A nephrotoxicity in rats. *Exp Nephrol* 2000; **8**: 161-172 [PMID: 10810233 DOI: 10.1159/000020664]

10 **Sahin G**, Akay OM, Bal C, Yalcin AU, Gulbas Z. The effect of calcineurin inhibitors on endothelial and platelet function in renal transplant patients. *Clin Nephrol* 2011; **76**: 218-225 [PMID: 21888859]

11 **Tomasiak M**, Rusak T, Gacko M, Stelmach H. Cyclosporine enhances platelet procoagulant activity. *Nephrol Dial Transplant* 2007; **22**: 1750-1756 [PMID: 17308321 DOI: 10.1093/ndt/gfl836]

12 **Verpooten GA**, Cools FJ, Van der Planken MG, Bedert LC, Claes R, Van Gaal LF, De Broe ME. Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. *Nephrol Dial Transplant* 1996; **11**: 347-351 [PMID: 8671791 DOI: 10.1093/oxfordjournals.ndt.a027265]

13 **Renner B**, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, Christians U, Thurman JM. Cyclosporine induces endothelial cell release of complement-activating microparticles. *J Am Soc Nephrol* 2013; **24**: 1849-1862 [PMID: 24092930 DOI: 10.1681/ASN.2012111064]

14 **Mulgaonkar S**, Kaufman DB. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients. *Clin Transplant* 2014; **28**: 1209-1224 [PMID: 25142257 DOI: 10.1111/ctr.12453]

15 **Sartelet H**, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E, Birembaut P, Chanard J, Rieu P. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. *Am J Transplant* 2005; **5**: 2441-2447 [PMID: 16162193 DOI: 10.1111/j.1600-6143.2005.01047.x]

16 **Miriuka SG**, Rao V, Peterson M, Tumiati L, Delgado DH, Mohan R, Ramzy D, Stewart D, Ross HJ, Waddell TK. mTOR inhibition induces endothelial progenitor cell death. *Am J Transplant* 2006; **6**: 2069-2079 [PMID: 16796720 DOI: 10.1111/j.1600-6143.2006.01433.x]

17 **Keir LS**, Firth R, Aponik L, Feitelberg D, Sakimoto S, Aguilar E, Welsh GI, Richards A, Usui Y, Satchell SC, Kuzmuk V, Coward RJ, Goult J, Bull KR, Sharma R, Bharti K, Westenskow PD, Michael IP, Saleem MA, Friedlander M. VEGF regulates local inhibitory complement proteins in the eye and kidney. *J Clin Invest* 2017; **127**: 199-214 [PMID: 27918307 DOI: 10.1172/JCI86418]

18 **Fortin MC**, Raymond MA, Madore F, Fugère JA, Pâquet M, St-Louis G, Hébert MJ. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. *Am J Transplant* 2004; **4**: 946-952 [PMID: 15147429 DOI: 10.1111/j.1600-6143.2004.00428.x]

19 **Robson M**, Côte I, Abbs I, Koffman G, Goldsmith D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? *Am J Transplant* 2003; **3**: 324-327 [PMID: 12614289 DOI: 10.1034/j.1600-6143.2003.00051.x]

20 **Nava F**, Cappelli G, Mori G, Granito M, Magnoni G, Botta C, Solazzo A, Fontana F, Baisi A, Bonucchi D. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation. *Transplant Proc* 2014; **46**: 2263-2268 [PMID: 25242766 DOI: 10.1016/j.transproceed.2014.07.062]

21 **Keller K**, Daniel C, Schöcklmann H, Endlich KH, Kerjaschki D, Johnson RJ, Hugo C. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy. *Nephrol Dial Transplant* 2006; **21**: 2724-2735 [PMID: 16861242 DOI: 10.1093/ndt/gfl340]

22 **Baas MC**, Gerdes VE, Ten Berge IJ, Heutinck KM, Florquin S, Meijers JC, Bemelman FJ. Treatment with everolimus is associated with a procoagulant state. *Thromb Res* 2013; **132**: 307-311 [PMID: 23906938 DOI: 10.1016/j.thromres.2013.07.004]

23 **Crew RJ**, Radhakrishnan J, Cohen DJ, Stern L, Goldstein M, Hardy M, D'Agati VD, Markowitz GS. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. *Nephrol Dial Transplant* 2005; **20**: 203-209 [PMID: 15632351 DOI: 10.1093/ndt/gfh334]

24 **Le Quintrec M**, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Frémeaux-Bacchi V. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. *Am J Transplant* 2013; **13**: 663-675 [PMID: 23356914 DOI: 10.1111/ajt.12077]

25 **Meehan SM**, Kremer J, Ali FN, Curley J, Marino S, Chang A, Kadambi PV. Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies. *Clin J Am Soc Nephrol* 2011; **6**: 395-403 [PMID: 20966124 DOI: 10.2215/CJN.05870710]

26 **Wu K**, Budde K, Schmidt D, Neumayer HH, Lehner L, Bamoulid J, Rudolph B. The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy. *Clin Transplant* 2016; **30**: 105-117 [PMID: 26448478 DOI: 10.1111/ctr.12645]

27 **Rane S**, Nada R, Minz M, Sakhuja V, Joshi K. Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients. *Transplant Proc* 2012; **44**: 713-716 [PMID: 22483475 DOI: 10.1016/j.transproceed.2011.11.052]

28 **De Keyzer K**, Van Laecke S, Peeters P, Vanholder R. De novo thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss. *Am J Nephrol* 2010; **32**: 491-496 [PMID: 20975262 DOI: 10.1159/000321328]

29 **Petrogiannis-Haliotis T**, Sakoulas G, Kirby J, Koralnik IJ, Dvorak AM, Monahan-Earley R, DE Girolami PC, DE Girolami U, Upton M, Major EO, Pfister LA, Joseph JT. BK-related polyomavirus vasculopathy in a renal-transplant recipient. *N Engl J Med* 2001; **345**: 1250-1255 [PMID: 11680445 DOI: 10.1056/NEJMoa010319]

30 **Ardalan MR**, Shoja MM, Tubbs RS, Jayne D. Parvovirus B19 microepidemic in renal transplant recipients with thrombotic microangiopathy and allograft vasculitis. *Exp Clin Transplant* 2008; **6**: 137-143 [PMID: 18816241]

31 **Waldman M**, Kopp JB. Parvovirus-B19-associated complications in renal transplant recipients. *Nat Clin Pract Nephrol* 2007; **3**: 540-550 [PMID: 17895931 DOI: 10.1038/ncpneph0609]

32 **Baid S**, Pascual M, Williams WW Jr, Tolkoff-Rubin N, Johnson SM, Collins B, Chung RT, Delmonico FL, Cosimi AB, Colvin RB. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. *J Am Soc Nephrol* 1999; **10**: 146-153 [PMID: 9890320]

33 **Baid-Agrawal S**, Farris AB 3rd, Pascual M, Mauiyyedi S, Farrell ML, Tolkoff-Rubin N, Collins AB, Frei U, Colvin RB. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. *Kidney Int* 2011; **80**: 879-885 [PMID: 21697808 DOI: 10.1038/ki.2011.194]

34 **Yamazaki S**, Takayama T, Inoue K, Higaki T, Makuuchi M. Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. *Transplantation* 2008; **86**: 1010-1011 [PMID: 18852671 DOI: 10.1097/TP.0b013e31818747d8]

35 **Dwyre DM**, Bell AM, Siechen K, Sethi S, Raife TJ. Disseminated histoplasmosis presenting as thrombotic microangiopathy. *Transfusion* 2006; **46**: 1221-1225 [PMID: 16836570 DOI: 10.1111/j.1537-2995.2006.00873.x]

36 **Sethi S**. Acute renal failure in a renal allograft: an unusual infectious cause of thrombotic microangiopathy. *Am J Kidney Dis* 2005; **46**: 159-162 [PMID: 15983970 DOI: 10.1053/j.ajkd.2004.11.026]

37 **de Vries DK**, van der Pol P, van Anken GE, van Gijlswijk DJ, Damman J, Lindeman JH, Reinders ME, Schaapherder AF, Kooten Cv. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. *Transplantation* 2013; **95**: 816-820 [PMID: 23348894 DOI: 10.1097/TP.0b013e31827e31c9]

38 **Pham PT**, Danovitch GM, Wilkinson AH, Gritsch HA, Pham PC, Eric TM, Kendrick E, Charles LR, Tsai HM. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. *Transplantation* 2002; **74**: 1077-1080 [PMID: 12438949 DOI: 10.1097/01.TP.0000038117.01138.08]

39 **Ulinski T**, Charpentier A, Colombat M, Desconclois C, Mougenot B, Fremaux-Bacchi V, Suberbielle C, Deschênes G, Bensman A, Veyradier A. From humoral rejection to generalized thrombotic microangiopathy--role of acquired ADAMTS13 deficiency in a renal allograft recipient. *Am J Transplant* 2006; **6**: 3030-3036 [PMID: 17294528 DOI: 10.1111/j.1600-6143.2006.01574.x]

40 **Lorcy N**, Rioux-Leclercq N, Lombard ML, Le Pogamp P, Vigneau C. Three kidneys, two diseases, one antibody? *Nephrol Dial Transplant* 2011; **26**: 3811-3813 [PMID: 21813829 DOI: 10.1093/ndt/gfr436]

41 **Chua JS**, Baelde HJ, Zandbergen M, Wilhelmus S, van Es LA, de Fijter JW, Bruijn JA, Bajema IM, Cohen D. Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. *J Am Soc Nephrol* 2015; **26**: 2239-2247 [PMID: 25573909 DOI: 10.1681/ASN.2014050429]

42 **George JN**, Nester CM. Syndromes of thrombotic microangiopathy. *N Engl J Med* 2014; **371**: 654-666 [PMID: 25119611 DOI: 10.1056/NEJMra1312353]

43 **Karthikeyan V**, Parasuraman R, Shah V, Vera E, Venkat KK. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. *Am J Transplant* 2003; **3**: 1289-1294 [PMID: 14510703 DOI: 10.1046/j.1600-6143.2003.00222.x]

44 **Nadasdy T**. Thrombotic microangiopathy in renal allografts: the diagnostic challenge. *Curr Opin Organ Transplant* 2014; **19**: 283-292 [PMID: 24811438 DOI: 10.1097/MOT.0000000000000074]

45 **Bouatou Y**, Bacchi VF, Villard J, Moll S, Martin PY, Hadaya K. Atypical Hemolytic Uremic Syndrome Recurrence after Renal Transplantation: C3-Glomerulonephritis as an Initial Presentation. *Transplant Direct* 2015; **1**: e9 [PMID: 27500215 DOI: 10.1097/TXD.0000000000000518]

46 **Matar D**, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. *Transplantation* 2014; **98**: 1205-1212 [PMID: 24933457 DOI: 10.1097/TP.0000000000000200]

47 **Noris M**, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. *Am J Transplant* 2010; **10**: 1517-1523 [PMID: 20642678 DOI: 10.1111/j.1600-6143.2010.03156.x]

48 **Noris M**, Remuzzi G. Atypical hemolytic-uremic syndrome. *N Engl J Med* 2009; **361**: 1676-1687 [PMID: 19846853 DOI: 10.1056/NEJMra0902814]

49 **Bresin E**, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M; European Working Party on Complement Genetics in Renal Diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. *J Am Soc Nephrol* 2013; **24**: 475-486 [PMID: 23431077 DOI: 10.1681/ASN.2012090884]

50 **Bresin E**, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. *Clin J Am Soc Nephrol* 2006; **1**: 88-99 [PMID: 17699195 DOI: 10.2215/CJN.00050505]

51 **Zafrani L**, Mariotte E, Darmon M, Canet E, Merceron S, Boutboul D, Veyradier A, Galicier L, Azoulay E. Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. *J Thromb Haemost* 2015; **13**: 380-389 [PMID: 25523333 DOI: 10.1111/jth.12826]

52 **Mise K**, Ubara Y, Matsumoto M, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Hoshino J, Sawa N, Ohashi K, Kokame K, Miyata T, Fujimura Y, Takaichi K. Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report. *BMC Nephrol* 2013; **14**: 156 [PMID: 23870247 DOI: 10.1186/1471-2369-14-156]

53 **Song D**, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, Yu F, Liu G, Zhao MH. The spectrum of renal thrombotic microangiopathy in lupus nephritis. *Arthritis Res Ther* 2013; **15**: R12 [PMID: 23320601 DOI: 10.1186/ar4142]

54 **Barbour TD**, Crosthwaite A, Chow K, Finlay MJ, Better N, Hughes PD, Cohney SJ. Antiphospholipid syndrome in renal transplantation. *Nephrology* (Carlton) 2014; **19**: 177-185 [PMID: 24548061 DOI: 10.1111/nep.12217]

55 **Canaud G**, Kamar N, Anglicheau D, Esposito L, Rabant M, Noël LH, Guilbeau-Frugier C, Sberro-Soussan R, Del Bello A, Martinez F, Zuber J, Rostaing L, Legendre C. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. *Am J Transplant* 2013; **13**: 2179-2185 [PMID: 23763583 DOI: 10.1111/ajt.12319]

56 **George JN**. The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. *Kidney Int Suppl* 2009; : S52-S54 [PMID: 19180137 DOI: 10.1038/ki.2008.622]

57 **Mariotte E**, Blet A, Galicier L, Darmon M, Parquet N, Lengline E, Boutboul D, Canet E, Traineau R, Schlemmer B, Veyradier A, Azoulay E. Unresponsive thrombotic thrombocytopenic purpura in critically ill adults. *Intensive Care Med* 2013; **39**: 1272-1281 [PMID: 23549631 DOI: 10.1007/s00134-013-2873-4]

58 **Goodship TH**, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. *Kidney Int* 2017; **91**: 539-551 [PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005]

59 **Schmidt CQ**, Herbert AP, Hocking HG, Uhrín D, Barlow PN. Translational mini-review series on complement factor H: structural and functional correlations for factor H. *Clin Exp Immunol* 2008; **151**: 14-24 [PMID: 18081691 DOI: 10.1111/j.1365-2249.2007.03553.x]

60 **Bettoni S**, Bresin E, Remuzzi G, Noris M, Donadelli R. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. *J Biol Chem* 2016; **291**: 8214-8230 [PMID: 26903516 DOI: 10.1074/jbc.M115.693119]

61 **Kim DD**, Song WC. Membrane complement regulatory proteins. *Clin Immunol* 2006; **118**: 127-136 [PMID: 16338172 DOI: 10.1016/j.clim.2005.10.014]

62 **Merle NS**, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement System Part I - Molecular Mechanisms of Activation and Regulation. *Front Immunol* 2015; **6**: 262 [PMID: 26082779 DOI: 10.3389/fimmu.2015.00262]

63 **Frimat M**, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. *Blood* 2013; **122**: 282-292 [PMID: 23692858 DOI: 10.1182/blood-2013-03-489245]

64 **Brocklebank V**, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. *Clin J Am Soc Nephrol* 2018; **13**: 300-317 [PMID: 29042465 DOI: 10.2215/CJN.00620117]

65 **Fremeaux-Bacchi V**, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. *Clin J Am Soc Nephrol* 2013; **8**: 554-562 [PMID: 23307876 DOI: 10.2215/CJN.04760512]

66 **Maga TK**, Meyer NC, Belsha C, Nishimura CJ, Zhang Y, Smith RJ. A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome. *Nephrol Dial Transplant* 2011; **26**: 739-741 [PMID: 20974643 DOI: 10.1093/ndt/gfq658]

67 **Zipfel PF**, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH, Skerka C. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. *PLoS Genet* 2007; **3**: e41 [PMID: 17367211 DOI: 10.1371/journal.pgen.0030041]

68 **Valoti E**, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G, Rodriguez de Cordoba S, Noris M. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. *J Am Soc Nephrol* 2015; **26**: 209-219 [PMID: 24904082 DOI: 10.1681/ASN.2013121339]

69 **Sethi S**, Haas M, Markowitz GS, D'Agati VD, Rennke HG, Jennette JC, Bajema IM, Alpers CE, Chang A, Cornell LD, Cosio FG, Fogo AB, Glassock RJ, Hariharan S, Kambham N, Lager DJ, Leung N, Mengel M, Nath KA, Roberts IS, Rovin BH, Seshan SV, Smith RJ, Walker PD, Winearls CG, Appel GB, Alexander MP, Cattran DC, Casado CA, Cook HT, De Vriese AS, Radhakrishnan J, Racusen LC, Ronco P, Fervenza FC. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. *J Am Soc Nephrol* 2016; **27**: 1278-1287 [PMID: 26567243 DOI: 10.1681/ASN.2015060612]

70 **Fremeaux-Bacchi V**, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Fridman WH. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. *J Med Genet* 2004; **41**: e84 [PMID: 15173250 DOI: 10.1136/jmg.2004.019083]

71 **Chan MR**, Thomas CP, Torrealba JR, Djamali A, Fernandez LA, Nishimura CJ, Smith RJ, Samaniego MD. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. *Am J Kidney Dis* 2009; **53**: 321-326 [PMID: 18805611 DOI: 10.1053/j.ajkd.2008.06.027]

72 **Bienaime F**, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautés-Fridman C, Villoutreix BO, Blom AM, Fremeaux-Bacchi V. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. *Kidney Int* 2010; **77**: 339-349 [PMID: 20016463 DOI: 10.1038/ki.2009.472]

73 **Fremeaux-Bacchi V**, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R, Fridman WH, Loirat C, Atkinson JP. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 2006; **17**: 2017-2025 [PMID: 16762990 DOI: 10.1681/ASN.2005101051]

74 **Salvadori M**, Bertoni E. Complement related kidney diseases: Recurrence after transplantation. *World J Transplant* 2016; **6**: 632-645 [PMID: 28058212 DOI: 10.5500/wjt.v6.i4.632]

75 **Delvaeye M**, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. *N Engl J Med* 2009; **361**: 345-357 [PMID: 19625716 DOI: 10.1056/NEJMoa0810739]

76 **Sinibaldi S**, Guzzo I, Piras R, Bresin E, Emma F, Dello Strologo L. Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. *Pediatr Transplant* 2013; **17**: E177-E181 [PMID: 24118826 DOI: 10.1111/petr.12151]

77 **Goicoechea de Jorge E**, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, López-Trascasa M, Sánchez-Corral P, Morgan BP, Rodríguez de Córdoba S. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. *Proc Natl Acad Sci USA* 2007; **104**: 240-245 [PMID: 17182750 DOI: 10.1073/pnas.0603420103]

78 **Roumenina LT**, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-Durey MA, Cayla M, Fridman WH, Macher MA, Ribes D, Moulonguet L, Rostaing L, Satchell SC, Mathieson PW, Sautes-Fridman C, Loirat C, Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. *Blood* 2009; **114**: 2837-2845 [PMID: 19584399 DOI: 10.1182/blood-2009-01-197640]

79 **Noris M**, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clin J Am Soc Nephrol* 2010; **5**: 1844-1859 [PMID: 20595690 DOI: 10.2215/CJN.02210310]

80 **Zuber J**, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. *Nat Rev Nephrol* 2011; **7**: 23-35 [PMID: 21102542 DOI: 10.1038/nrneph.2010.155]

81 **Epand RM**, So V, Jennings W, Khadka B, Gupta RS, Lemaire M. Diacylglycerol Kinase-ε: Properties and Biological Roles. *Front Cell Dev Biol* 2016; **4**: 112 [PMID: 27803897 DOI: 10.3389/fcell.2016.00112]

82 **Azukaitis K**, Simkova E, Majid MA, Galiano M, Benz K, Amann K, Bockmeyer C, Gajjar R, Meyers KE, Cheong HI, Lange-Sperandio B, Jungraithmayr T, Frémeaux-Bacchi V, Bergmann C, Bereczki C, Miklaszewska M, Csuka D, Prohászka Z, Gipson P, Sampson MG, Lemaire M, Schaefer F. The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε. *J Am Soc Nephrol* 2017; **28**: 3066-3075 [PMID: 28526779 DOI: 10.1681/ASN.2017010031]

83 **Ruggenenti P**. Post-transplant hemolytic-uremic syndrome. *Kidney Int* 2002; **62**: 1093-1104 [PMID: 12164897 DOI: 10.1046/j.1523-1755.2002.00543.x]

84 **Loirat C**, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Frémeaux-Bacchi V; HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. *Pediatr Nephrol* 2016; **31**: 15-39 [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8]

85 **Caprioli J**, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G; International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. *Blood* 2006; **108**: 1267-1279 [PMID: 16621965 DOI: 10.1182/blood-2005-10-007252]

86 **Kavanagh D**, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. *Semin Nephrol* 2013; **33**: 508-530 [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003]

87 **Wikipedia**. Penetrance. Available from: URL: https://en.wikipedia.org/wiki/Penetrance

88 **Sansbury FH**, Cordell HJ, Bingham C, Bromilow G, Nicholls A, Powell R, Shields B, Smyth L, Warwicker P, Strain L, Wilson V, Goodship JA, Goodship TH, Turnpenny PD. Factors determining penetrance in familial atypical haemolytic uraemic syndrome. *J Med Genet* 2014; **51**: 756-764 [PMID: 25261570 DOI: 10.1136/jmedgenet-2014-102498]

89 **Noris M**, Remuzzi G. Hemolytic uremic syndrome. *J Am Soc Nephrol* 2005; **16**: 1035-1050 [PMID: 15728781 DOI: 10.1681/ASN.2004100861]

90 **Pickering MC**, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT. C3 glomerulopathy: consensus report. *Kidney Int* 2013; **84**: 1079-1089 [PMID: 24172683 DOI: 10.1038/ki.2013.377]

91 **Hou J**, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD. Toward a working definition of C3 glomerulopathy by immunofluorescence. *Kidney Int* 2014; **85**: 450-456 [PMID: 24067430 DOI: 10.1038/ki.2013.340]

92 **Larsen CP**, Ambuzs JM, Bonsib SM, Boils CL, Cossey LN, Messias NC, Silva FG, Wang YH, Gokden N, Walker PD. Membranous-like glomerulopathy with masked IgG kappa deposits. *Kidney Int* 2014; **86**: 154-161 [PMID: 24429395 DOI: 10.1038/ki.2013.548]

93 **Larsen CP**, Messias NC, Walker PD, Fidler ME, Cornell LD, Hernandez LH, Alexander MP, Sethi S, Nasr SH. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. *Kidney Int* 2015; **88**: 867-873 [PMID: 26154922 DOI: 10.1038/ki.2015.195]

94 **Cook HT**. C4d Staining in the Diagnosis of C3 Glomerulopathy. *J Am Soc Nephrol* 2015; **26**: 2609-2611 [PMID: 25991042 DOI: 10.1681/ASN.2015040433]

95 **Sethi S**, Nasr SH, De Vriese AS, Fervenza FC. C4d as a Diagnostic Tool in Proliferative GN. *J Am Soc Nephrol* 2015; **26**: 2852-2859 [PMID: 25991041 DOI: 10.1681/ASN.2014040406]

96 **West CD**, Witte DP, McAdams AJ. Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2. *Am J Kidney Dis* 2001; **37**: 1120-1130 [PMID: 11382679 DOI: 10.1053/ajkd.2001.24511]

97 **Sethi S**, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. *Kidney Int* 2012; **82**: 465-473 [PMID: 22673887 DOI: 10.1038/ki.2012.212]

98 **Sethi S**, Gamez JD, Vrana JA, Theis JD, Bergen HR 3rd, Zipfel PF, Dogan A, Smith RJ. Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. *Kidney Int* 2009; **75**: 952-960 [PMID: 19177158 DOI: 10.1038/ki.2008.657]

99 **Recalde S**, Tortajada A, Subias M, Anter J, Blasco M, Maranta R, Coco R, Pinto S, Noris M, García-Layana A, Rodríguez de Córdoba S. Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. *J Am Soc Nephrol* 2016; **27**: 1305-1311 [PMID: 26376859 DOI: 10.1681/ASN.2015050580]

100 **Gerber A**, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. *J Infect Dis* 2002; **186**: 493-500 [PMID: 12195376 DOI: 10.1086/341940]

101 **Servais A**, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. *Kidney Int* 2012; **82**: 454-464 [PMID: 22456601 DOI: 10.1038/ki.2012.63]

102 **Angioi A**, Fervenza FC, Sethi S, Zhang Y, Smith RJ, Murray D, Van Praet J, Pani A, De Vriese AS. Diagnosis of complement alternative pathway disorders. *Kidney Int* 2016; **89**: 278-288 [PMID: 26806831 DOI: 10.1016/j.kint.2015.12.003]

103 **Abarrategui-Garrido C**, Martínez-Barricarte R, López-Trascasa M, de Córdoba SR, Sánchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. *Blood* 2009; **114**: 4261-4271 [PMID: 19745068 DOI: 10.1182/blood-2009-05-223834]

104 **Lemaire M**, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nürnberg G, Altmüller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nürnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. *Nat Genet* 2013; **45**: 531-536 [PMID: 23542698 DOI: 10.1038/ng.2590]

105 **Maga TK**, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. *Hum Mutat* 2010; **31**: E1445-E1460 [PMID: 20513133 DOI: 10.1002/humu.21256]

106 **Esparza-Gordillo J**, Goicoechea de Jorge E, Buil A, Carreras Berges L, López-Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. *Hum Mol Genet* 2005; **14**: 703-712 [PMID: 15661753 DOI: 10.1093/hmg/ddi066]

107 **Challis RC**, Araujo GS, Wong EK, Anderson HE, Awan A, Dorman AM, Waldron M, Wilson V, Brocklebank V, Strain L, Morgan BP, Harris CL, Marchbank KJ, Goodship TH, Kavanagh D. A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome. *J Am Soc Nephrol* 2016; **27**: 1617-1624 [PMID: 26490391 DOI: 10.1681/ASN.2015010100]

108 **Chen Q**, Wiesener M, Eberhardt HU, Hartmann A, Uzonyi B, Kirschfink M, Amann K, Buettner M, Goodship T, Hugo C, Skerka C, Zipfel PF. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. *J Clin Invest* 2014; **124**: 145-155 [PMID: 24334459 DOI: 10.1172/JCI71866]

109 **Gale DP**, de Jorge EG, Cook HT, Martinez-Barricarte R, Hadjisavvas A, McLean AG, Pusey CD, Pierides A, Kyriacou K, Athanasiou Y, Voskarides K, Deltas C, Palmer A, Frémeaux-Bacchi V, de Cordoba SR, Maxwell PH, Pickering MC. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. *Lancet* 2010; **376**: 794-801 [PMID: 20800271 DOI: 10.1016/S0140-6736(10)60670-8]

110 **Tortajada A**, Yébenes H, Abarrategui-Garrido C, Anter J, García-Fernández JM, Martínez-Barricarte R, Alba-Domínguez M, Malik TH, Bedoya R, Cabrera Pérez R, López Trascasa M, Pickering MC, Harris CL, Sánchez-Corral P, Llorca O, Rodríguez de Córdoba S. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. *J Clin Invest* 2013; **123**: 2434-2446 [PMID: 23728178 DOI: 10.1172/JCI68280]

111 **Venables JP**, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A, Wood KM, Goodship JA, Goodship TH. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. *PLoS Med* 2006; **3**: e431 [PMID: 17076561 DOI: 10.1371/journal.pmed.0030431]

112 **Noris M**, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. *Curr Opin Nephrol Hypertens* 2013; **22**: 704-712 [PMID: 24076560 DOI: 10.1097/MNH.0b013e328365b3fe]

113 **Zuber J**, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. *Nat Rev Nephrol* 2012; **8**: 643-657 [PMID: 23026949 DOI: 10.1038/nrneph.2012.214]

114 **Richards S**, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015; **17**: 405-424 [PMID: 25741868 DOI: 10.1038/gim.2015.30]

115 **Manuelian T**, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. *J Clin Invest* 2003; **111**: 1181-1190 [PMID: 12697737 DOI: 10.1172/JCI16651]

116 **Marinozzi MC**, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C, Smith RJ, Noris M, Halbwachs-Mecarelli L, Donadelli R, Fremeaux-Bacchi V, Roumenina LT. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? *J Am Soc Nephrol* 2014; **25**: 2053-2065 [PMID: 24652797 DOI: 10.1681/ASN.2013070796]

117 **Noris M**, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. *Blood* 2014; **124**: 1715-1726 [PMID: 25037630 DOI: 10.1182/blood-2014-02-558296]

118 **Pérez-Caballero D**, González-Rubio C, Gallardo ME, Vera M, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. *Am J Hum Genet* 2001; **68**: 478-484 [PMID: 11170895 DOI: 10.1086/318201]

119 **Sánchez-Corral P**, Pérez-Caballero D, Huarte O, Simckes AM, Goicoechea E, López-Trascasa M, de Córdoba SR. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. *Am J Hum Genet* 2002; **71**: 1285-1295 [PMID: 12424708 DOI: 10.1086/344515]

120 **Schramm EC**, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S, Smith RJ, Noris M, Goodship T, Atkinson JP, Fremeaux-Bacchi V. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. *Blood* 2015; **125**: 2359-2369 [PMID: 25608561 DOI: 10.1182/blood-2014-10-609073]

121 **Ståhl AL**, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, Gutierrez A, Beringer O, Zipfel PF, Karpman D. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. *Blood* 2008; **111**: 5307-5315 [PMID: 18268093 DOI: 10.1182/blood-2007-08-106153]

122 **Bernabéu-Herrero ME**, Jiménez-Alcázar M, Anter J, Pinto S, Sánchez Chinchilla D, Garrido S, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. *Mol Immunol* 2015; **67**: 276-286 [PMID: 26163426 DOI: 10.1016/j.molimm.2015.06.021]

123 **Caprioli J**, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M; International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. *Hum Mol Genet* 2003; **12**: 3385-3395 [PMID: 14583443 DOI: 10.1093/hmg/ddg363]

124 **Harris CL**, Heurich M, Rodriguez de Cordoba S, Morgan BP. The complotype: dictating risk for inflammation and infection. *Trends Immunol* 2012; **33**: 513-521 [PMID: 22749446 DOI: 10.1016/j.it.2012.06.001]

125 **Pickering MC**, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR, Botto M. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. *J Exp Med* 2007; **204**: 1249-1256 [PMID: 17517971 DOI: 10.1084/jem.20070301]

126 **Sánchez Chinchilla D**, Pinto S, Hoppe B, Adragna M, Lopez L, Justa Roldan ML, Peña A, Lopez Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S. Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome. *Clin J Am Soc Nephrol* 2014; **9**: 1611-1619 [PMID: 25135762 DOI: 10.2215/CJN.01640214]

127 **Zuber J**, Le Quintrec M, Morris H, Frémeaux-Bacchi V, Loirat C, Legendre C. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. *Transplant Rev* (Orlando) 2013; **27**: 117-125 [PMID: 23937869 DOI: 10.1016/j.trre.2013.07.003]

128 **Chua S**, Wong G, Lim WH. The importance of genetic mutation screening to determine retransplantation following failed kidney allograft from recurrent atypical haemolytic ureamic syndrome. *BMJ Case Rep* 2014; **2014:** pii: bcr2013202875 [PMID: 24671321 DOI: 10.1136/bcr-2013-202875]

129 **Kais H**, Nourredine C, Raoudha B, Emira C, Tarek S, Fehmi S, Ezzedine B, Jalel H, Jamel M. Treatment of Tacrolimus-associated thrombotic microangiopathy in renal transplant recipient with fresh frozen plasma: A case report. *Saudi J Kidney Dis Transpl* 2006; **17**: 58-61 [PMID: 17297539]

130 **Young BA**, Marsh CL, Alpers CE, Davis CL. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. *Am J Kidney Dis* 1996; **28**: 561-571 [PMID: 8840947 DOI: 10.1016/S0272-6386(96)90468-0]

131 **Cortina G**, Trojer R, Waldegger S, Schneeberger S, Gut N, Hofer J. De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus. *Pediatr Nephrol* 2015; **30**: 693-697 [PMID: 25577332 DOI: 10.1007/s00467-014-3036-8]

132 **Nwaba A**, MacQuillan G, Adams LA, Garas G, Delriviere L, Augustson B, DeBoer B, Moody H, Jeffrey GP. Tacrolimus-induced thrombotic microangiopathy in orthotopic liver transplant patients: case series of four patients. *Intern Med J* 2013; **43**: 328-333 [PMID: 23441660 DOI: 10.1111/imj.12048]

133 **Franco A**, Hernandez D, Capdevilla L, Errasti P, Gonzalez M, Ruiz JC, Sanchez J; HUS-Sirolimus Spanish Study Group. De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. *Transplant Proc* 2003; **35**: 1764-1766 [PMID: 12962787 DOI: 10.1016/S0041-1345(03)00614-6]

134 **Epperla N**, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. *Transfusion* 2017; **57**: 2775-2781 [PMID: 28836275 DOI: 10.1111/trf.14263]

135 **Rock GA**, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. *N Engl J Med* 1991; **325**: 393-397 [PMID: 2062330 DOI: 10.1056/NEJM199108083250604]

136 **Bell WR**, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. *N Engl J Med* 1991; **325**: 398-403 [PMID: 2062331 DOI: 10.1056/NEJM199108083250605]

137 **Djamali A**, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. *Am J Transplant* 2014; **14**: 255-271 [PMID: 24401076 DOI: 10.1111/ajt.12589]

138 **Ashman N**, Chapagain A, Dobbie H, Raftery MJ, Sheaff MT, Yaqoob MM. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. *Am J Transplant* 2009; **9**: 424-427 [PMID: 19120084 DOI: 10.1111/j.1600-6143.2008.02482.x]

139 **Koppula S**, Yost SE, Sussman A, Bracamonte ER, Kaplan B. Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients. *Clin Transplant* 2013; **27**: 591-597 [PMID: 23923969 DOI: 10.1111/ctr.12170]

140 **Cicora F**, Paz M, Mos F, Roberti J. Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy. *Case Rep Med* 2013; **2013**: 260254 [PMID: 24198835 DOI: 10.1155/2013/260254]

141 **Legendre CM**, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med* 2013; **368**: 2169-2181 [PMID: 23738544 DOI: 10.1056/NEJMoa1208981]

142 **Shochet L**, Kanellis J, Simpson I, Ta J, Mulley W. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab. *Nephrology* (Carlton) 2017; **22** Suppl 1: 23-27 [PMID: 28176480 DOI: 10.1111/nep.12936]

143 **Dedhia P**, Govil A, Mogilishetty G, Alloway RR, Woodle ES, Abu Jawdeh BG. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report. *Transplant Proc* 2017; **49**: 188-192 [PMID: 28104134 DOI: 10.1016/j.transproceed.2016.11.008]

144 **Ikeda T**, Okumi M, Unagami K, Kanzawa T, Sawada A, Kawanishi K, Omoto K, Ishida H, Tanabe K. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab. *Nephrology* (Carlton) 2016; **21 Suppl 1**: 35-40 [PMID: 26970541 DOI: 10.1111/nep.12768]

145 **Safa K**, Logan MS, Batal I, Gabardi S, Rennke HG, Abdi R. Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report. *Clin Nephrol* 2015; **83**: 125-129 [PMID: 24495904 DOI: 10.5414/CN108163]

146 **Chandran S**, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report. *Transplant Proc* 2011; **43**: 2097-2101 [PMID: 21693335 DOI: 10.1016/j.transproceed.2011.02.064]

147 **Wilson CH**, Brown AL, White SA, Goodship TH, Sheerin NS, Manas DM. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. *Transplantation* 2011; **92**: e42-e43 [PMID: 21989273 DOI: 10.1097/TP.0b013e318230c0bd]

148 **Stegall MD**, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. *Am J Transplant* 2011; **11**: 2405-2413 [PMID: 21942930 DOI: 10.1111/j.1600-6143.2011.03757.x]

149 **González-Roncero F**, Suñer M, Bernal G, Cabello V, Toro M, Pereira P, Angel Gentil M. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. *Transplant Proc* 2012; **44**: 2690-2694 [PMID: 23146495 DOI: 10.1016/j.transproceed.2012.09.038]

150 **Chehade H**, Rotman S, Matter M, Girardin E, Aubert V, Pascual M. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient. *Pediatrics* 2015; **135**: e551-e555 [PMID: 25624380 DOI: 10.1542/peds.2014-2275]

151 **Locke JE**, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, Montgomery RA. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. *Am J Transplant* 2009; **9**: 231-235 [PMID: 18976298 DOI: 10.1111/j.1600-6143.2008.02451.x]

152 **Lonze BE**, Dagher NN, Simpkins CE, Locke JE, Singer AL, Segev DL, Zachary AA, Montgomery RA. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. *Am J Transplant* 2010; **10**: 2154-2160 [PMID: 20636451 DOI: 10.1111/j.1600-6143.2010.03191.x]

153 **Stewart ZA**, Collins TE, Schlueter AJ, Raife TI, Holanda DG, Nair R, Reed AI, Thomas CP. Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. *Transplant Proc* 2012; **44**: 3033-3036 [PMID: 23195021 DOI: 10.1016/j.transproceed.2012.03.053]

154 **Tran D**, Boucher A, Collette S, Payette A, Royal V, Senécal L. Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature. *Case Rep Transplant* 2016; **2016**: 9874261 [PMID: 27478676 DOI: 10.1155/2016/9874261]

155 **Orandi BJ**, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. *Transplantation* 2014; **98**: 857-863 [PMID: 25121475 DOI: 10.1097/TP.0000000000000298]

156 **Kulkarni S**, Kirkiles-Smith NC, Deng YH, Formica RN, Moeckel G, Broecker V, Bow L, Tomlin R, Pober JS. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. *Am J Transplant* 2017; **17**: 682-691 [PMID: 27501352 DOI: 10.1111/ajt.14001]

157 **Cornell LD**, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. *Am J Transplant* 2015; **15**: 1293-1302 [PMID: 25731800 DOI: 10.1111/ajt.13168]

158 **Vernon KA**, Gale DP, de Jorge EG, McLean AG, Galliford J, Pierides A, Maxwell PH, Taube D, Pickering MC, Cook HT. Recurrence of complement factor H-related protein 5 nephropathy in a renal transplant. *Am J Transplant* 2011; **11**: 152-155 [PMID: 21114651 DOI: 10.1111/j.1600-6143.2010.03333.x]

159 **Loirat C**, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. *Pediatr Transplant* 2008; **12**: 619-629 [PMID: 18482212 DOI: 10.1111/j.1399-3046.2008.00910.x]

160 **Noris M**, Remuzzi G. Overview of complement activation and regulation. *Semin Nephrol* 2013; **33**: 479-492 [PMID: 24161035 DOI: 10.1016/j.semnephrol.2013.08.001]

161 **Zuber J**, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C; French Study Group for Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. *Am J Transplant* 2012; **12**: 3337-3354 [PMID: 22958221 DOI: 10.1111/j.1600-6143.2012.04252.x]

162 **Goicoechea de Jorge E**, Caesar JJ, Malik TH, Patel M, Colledge M, Johnson S, Hakobyan S, Morgan BP, Harris CL, Pickering MC, Lea SM. Dimerization of complement factor H-related proteins modulates complement activation in vivo. *Proc Natl Acad Sci USA* 2013; **110**: 4685-4690 [PMID: 23487775 DOI: 10.1073/pnas.1219260110]

163 **Kwon T**, Dragon-Durey MA, Macher MA, Baudouin V, Maisin A, Peuchmaur M, Fremeaux-Bacchi V, Loirat C. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. *Nephrol Dial Transplant* 2008; **23**: 2088-2090 [PMID: 18326881 DOI: 10.1093/ndt/gfn063]

164 **Waters AM**, Pappworth I, Marchbank K, Bockenhauer D, Tullus K, Pickering MC, Strain L, Sebire N, Shroff R, Marks SD, Goodship TH, Rees L. Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. *Am J Transplant* 2010; **10**: 168-172 [PMID: 19951285 DOI: 10.1111/j.1600-6143.2009.02870.x]

165 **Zimmerhackl LB**, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. *N Engl J Med* 2010; **362**: 1746-1748 [PMID: 20445192 DOI: 10.1056/NEJMc1001060]

166 **Román-Ortiz E**, Mendizabal Oteiza S, Pinto S, López-Trascasa M, Sánchez-Corral P, Rodríguez de Cordoba S. Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene. *Pediatr Nephrol* 2014; **29**: 149-153 [PMID: 23982707 DOI: 10.1007/s00467-013-2591-8]

167 **Nester C**, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. *Clin J Am Soc Nephrol* 2011; **6**: 1488-1494 [PMID: 21617085 DOI: 10.2215/CJN.10181110]

168 **Krid S**, Roumenina LT, Beury D, Charbit M, Boyer O, Frémeaux-Bacchi V, Niaudet P. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. *Am J Transplant* 2012; **12**: 1938-1944 [PMID: 22494769 DOI: 10.1111/j.1600-6143.2012.04051.x]

169 **Donne RL**, Abbs I, Barany P, Elinder CG, Little M, Conlon P, Goodship TH. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. *Am J Kidney Dis* 2002; **40**: E22 [PMID: 12460067 DOI: 10.1053/ajkd.2002.36938]

170 **Povey H**, Vundru R, Junglee N, Jibani M. Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. *Clin Nephrol* 2014; **82**: 326-331 [PMID: 23557793 DOI: 10.5414/CN107958]

171 **Licht C**, Heinen S, Józsi M, Löschmann I, Saunders RE, Perkins SJ, Waldherr R, Skerka C, Kirschfink M, Hoppe B, Zipfel PF. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). *Kidney Int* 2006; **70**: 42-50 [PMID: 16612335 DOI: 10.1038/sj.ki.5000269]

172 **Dragon-Durey MA**, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. *J Am Soc Nephrol* 2010; **21**: 2180-2187 [PMID: 21051740 DOI: 10.1681/ASN.2010030315]

173 **Khandelwal P**, Gupta A, Sinha A, Saini S, Hari P, Dragon Durey MA, Bagga A. Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. *Pediatr Nephrol* 2015; **30**: 451-457 [PMID: 25217328 DOI: 10.1007/s00467-014-2948-7]

174 **Sinha A**, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, George A, Bal V, Singh G, Dinda AK, Hari P, Rath S, Dragon-Durey MA, Bagga A; Indian HUS Registry. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. *Kidney Int* 2014; **85**: 1151-1160 [PMID: 24088957 DOI: 10.1038/ki.2013.373]

175 **Tanimoto T**, Oshima Y, Kami M. Eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med* 2013; **369**: 1378-1379 [PMID: 24088109 DOI: 10.1056/NEJMc1308826]

176 **Sheerin NS**, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. *QJM* 2016; **109**: 27-33 [PMID: 25899302 DOI: 10.1093/qjmed/hcv082]

177 **Wetzels JF**, van de Kar NC. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome. *Am J Kidney Dis* 2015; **65**: 342 [PMID: 25616634 DOI: 10.1053/j.ajkd.2014.04.039]

178 **Ardissino G**, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. *Am J Kidney Dis* 2015; **66**: 172-173 [PMID: 26111906 DOI: 10.1053/j.ajkd.2015.04.010]

179 **Verhave JC**, Westra D, van Hamersvelt HW, van Helden M, van de Kar NC, Wetzels JF. Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome. *Neth J Med* 2013; **71**: 342-347 [PMID: 24038559]

180 **Licht C**, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. *Kidney Int* 2015; **87**: 1061-1073 [PMID: 25651368 DOI: 10.1038/ki.2014.423]

181 **Coppo R**, Bonaudo R, Peruzzi RL, Amore A, Brunati A, Romagnoli R, Salizzoni M, Galbusera M, Gotti E, Daina E, Noris M, Remuzzi G. Liver transplantation for aHUS: still needed in the eculizumab era? *Pediatr Nephrol* 2016; **31**: 759-768 [PMID: 26604087 DOI: 10.1007/s00467-015-3278-0]

182 **Zhang Y**, Nester CM, Holanda DG, Marsh HC, Hammond RA, Thomas LJ, Meyer NC, Hunsicker LG, Sethi S, Smith RJ. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. *J Am Soc Nephrol* 2013; **24**: 1820-1829 [PMID: 23907509 DOI: 10.1681/ASN.2013010045]

183 **Zhang Y**, Shao D, Ricklin D, Hilkin BM, Nester CM, Lambris JD, Smith RJ. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. *Immunobiology* 2015; **220**: 993-998 [PMID: 25982307 DOI: 10.1016/j.imbio.2015.04.001]

184 **Paixão-Cavalcante D**, Torreira E, Lindorfer MA, Rodriguez de Cordoba S, Morgan BP, Taylor RP, Llorca O, Harris CL. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors. *J Immunol* 2014; **192**: 4844-4851 [PMID: 24729617 DOI: 10.4049/jimmunol.1303131]

**P-Reviewer:** Sanchez-Zapardiel E **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Transplantation

**Country of origin:** United Kingdom

**Peer-review report classification**





Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Acute and chronic thrombotic microangiopathy and calcineurin inhibitors-associated arteriolopathy with severe acute ischemic tubular lesions.** A: Advanced interstitial inflammatory fibrosis (Masson trichrome stain); B: IF, diffuse and segmental C3; C: C1q (C) deposits within glomerular capillary walls; D: Diffuse acute and chronic arteriolar and glomerular TMA lesions on LM (D). (Adapted from: Yassine *et al*[45]).



**Figure 2 Spectrum of thrombotic microangiopathy**[64]**.** AAV: ANCA-associated vasculitis; ADAMTS13: A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; aHUS: Atypical hemolytic uremic syndrome; C3G: C3 glomerulopathy; CAPS: Catastrophic antiphospholipid syndrome; cblC: Cobalamin C type; *DGKE*: Gene encoding diacylglycerol kinase ε; FH: Factor H; HELLP: Syndrome of hemolysis, elevated liver enzymes, and low platelets; HUS: Hemolytic uremic syndrome; IgAN: IgA nephropathy; MN: Membranous nephropathy; MPGN: Membranoproliferative GN; SRC: Scleroderma renal crisis; STEC: Shiga toxin–producing *Escherichia coli;* TMA: Thrombotic microangiopathy; TTP: Thrombotic thrombocytopenic purpura.

Thrombomodulin (THBD)

Genes associated only with aHUS

*Complement genes:*

Complement Factor H (CFH)

Complement Factor H-related genes 1 to 5 (CFHR1-5)

Membrane cofactor protein (MCP)

Complement Factor I (CFI)

Complement Factor B (CFB)

Complement Component 3 (C3)

*Non-complement genes:*

• Diacylglycerol kinase-ε (DGKE)

Genes associated with aHUS & C3G

1. CFH C-terminal variants associated with normal FH expression levels
2. Gene conversion events and genomic rearrangements between CFH & CFHR1 or CFHR3 resulting in FH-FHR & FHR-FH hybrid proteins
3. C3 pathogenic variants (i.e., p.R161W and p.I1157T)
4. CFH- H3 and MCP *ggaac* aHUS risk haplotypes
5. Absence of FHR-1 usually associated with homozygous deletion of the CFHR3- CFHR1 genes, which is a common CNV and is strongly associated with development of FH autoantibodies

aHUS prototypical genetic variants

**Figure 3 Genetic drivers in atypical hemolytic uremic syndrome (Adapted from: Goodship *et al*[58]).** aHUS: Atypical hemolytic uremic syndrome; C3G: C3 glomerulopathy; CNV: Copy number variation; SCR: Short consensus repeat.

**Low risk:**

* Isolated MCP mutations
* Persistently negative FH autoantibodies**.**


**High risk** (50-100%):


* Previous early recurrence.
* Pathogenic mutations1
* Gain-of-functionmutations

**Moderate risk:**

* No mutation identified
* Isolated CFI mutations
* Insignificant complement gene mutation
* Persistent low titer FH autoantibody.

**Figure 4 Prophylaxis against atypical hemolytic uremic syndrome recurrence in allograft based on a risk-assessment strategy[96] (Adapted from: Goodship *et al*[58]).** 1Requires complete screening of all genes implicated in aHUS; 2Prophylactic regimens are based on local center protocols; no trial data exist to support superiority of one protocol over another; 3Liver transplantation can be considered for renal transplant recipients with liver-derived complement protein abnormalities, uncontrolled disease activity despite eculizumab therapy or financial considerations regarding cost of long-term eculizumab therapy; 4Decision to perform or not to perform prophylactic plasma exchange or complement inhibition is left to the discretion of the clinician. aHUS: Atypical hemolytic uremic syndrome; *CFI*: Complement factor I gene; FH: Complement factor H protein; *MCP*: Membrane cofactor protein gene.

**Figure 5** **Treatment of complement factor H autoantibody-mediated atypical hemolytic uremic syndrome.** There are no prospective controlled studies in patients with atypical hemolytic uremic syndrome (aHUS) due to anti–factor H protein (FH) antibodies, and thus the proposed management is based on a pediatric consensus[84] (Adapted from: Goodship *et al*[58]). aAbnormal titer depends on the testing laboratory; bThe decision to use plasma therapy versus eculizumab will be based on patient age and local resource availability; cCyclophosphamide, rituximab, or mycophenolate mofetil; dThe decision to continue anticomplement therapy indefinitely is not informed by data; eThe interval may be monthly or quarterly and is based on local resources; fThis recommendation is based on limited retrospective case reviews[172-174].



**Figure 6 Recommendations for cessation of treatment with complement inhibitors.** There are no prospective controlled studies in patients with aHUS to define criteria for discontinuation of eculizumab therapy. This flow diagram is based on expert opinion[176-178]. Discontinuation can be considered on a case-by-case basis in patients after at least 6-12 mo of treatment and at least 3 mo of normalization (or stabilization in the case of residual CKD) of kidney function. Earlier cessation (at 3 mo) may be considered in patients (especially children) with pathogenic variants in MCP if there has been rapid remission and recovery of renal function. Patients on dialysis, eculizumab should be maintained for at least 4 to 6 mo before discontinuation. In this setting, assessment of fibrotic changes in kidney biopsy may be helpful. In transplant patients, especially patients who have lost previous allografts, discontinuation is not recommended. Adapted from: Goodship *et al*[58]. aHUS: Atypical hemolytic uremic syndrome.

**Table 1 Morphological features in microangiopathy**

|  |  |
| --- | --- |
| Active lesions | Chronic lesions |
| Glomeruli: Thrombi - Endothelial swelling or denudation - Fragmented RBCs - Subendothelial flocculent material. EM: Mesangiolysis - Microaneurysms | Glomeruli: LM: Double contours of peripheral capillary walls, with variable mesangial interposition - EM: New subendothelial basement membrane - Widening of the subendothelial zone |
| Arterioles: Thrombi - Endothelial swelling or denudation-Intramural fibrin-Fragmented red blood cells-Intimal swelling-Myocyte necrosis | Arterioles: Hyaline deposits |
| Arteries: Thrombi - Myxoid intimal swelling -Intramural fibrin- Fragmented red blood cells | Arteries: Fibrous intimal thickening with concentric lamination (onion skin) |

Adapted from: Goodship *et al*[58]. EM: Electron microscopy; LM: Light microscopy.

**Table 2 Risk of atypical hemolytic uremic syndrome recurrence according to the implicated genetic abnormality**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Gene mutation | Location | Functional impact | Mutation frequency in aHUS (%) | Recurrence after transplantation (%) |
| *CFH* | Plasma | Loss | 20-30 | 75-90 |
| *CFI* | Plasma | Loss | 2-12 | 45-80 |
| *CFB* | Plasma | Gain | 1-2 | 100 |
| *C3* | Plasma | Gain | 5-10 | 40-70 |
| *MCP* | Membrane | Loss | 10-15 | 15-20 |
| *THBD* | Membrane | Loss | 5 | One case |
| *Homozygous*  *CFHR1 del* (3%-8%) | Circulating | Undetermined | 14-23  (> 90% with anti-CHF AB) | NA |

Adapted from Salvadori *et al*[74]. NA: Not available; *CFH*: Complement factor H; *CFI*: Complement factor I; *MCP*: Membrane cofactor protein; *THBD*: Thrombomodulin.

**Table 3 Complement studies for atypical hemolytic uremic syndrome**

|  |  |
| --- | --- |
| **Complement test** | **aHUS** |
| Complement protein levels | C3, C4, FB1, C51 |
| Complement regulatory protein levels | FH, FI, Properdin1, CD462 |
| Complement split products | C3c1, C3d1, Bb1, sC5b-91 |
| Complement functional assays | CH50, AH50, hemolytic assays, FH assays1 |
| Autoantibodies | Anti-FH |
| Genetic screening | CFH, CFI, C3, CD46, CFB  Genomic rearrangements across the FH-FHR locus (*e.g.*, by MLPA)  Sequencing of coding regions and assessment of CNV  Non-complement genetic screening includes THBD and DGKE |

1Currently available only at specific laboratories; they are research and not clinically validated assays; 2CD46 is also known as MCP. Adapted from: Goodship *et al*[58]. AH50: Alternative pathway hemolytic assay; C3: Complement component 3; C4: Complement component 4; C5: Complement component 5; *CFB*: Complement factor B gene; *CFH*: Complement factor H gene; *CFHR*: Complement factor H related genes; CFI: Complement factor I gene; CH50: Classical pathway hemolytic assay; CNV: Copy number variation; *DGKE* gene: Diacylgylcerol kinase epsilon gene; FB: Complement factor B; FH: Complement factor H; FI: Complement factor I; MLPA: Multiplex ligation-dependent probe amplification; sC5b-9: Soluble C5b-9; THBD: Thrombomodulin; aHUS: Atypical hemolytic uremic syndrome.

**Table 4 Genotype-phenotype correlations in atypical hemolytic uremic syndrome (data refer to the period before introduction of eculizumab)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Gene** | **Risk of death or ESRD at onset or first year** | **Risk of recurrence** | **Risk of death or ESRD after 3-5 yr** | **Risk of recurrence in allograft** |
| *CFH* or *CFH-CFHR1/3* hybrid genes | 50%-70% | 50% | 75% | 75%-90% |
| *CFI* | 50% | 10%-30% | 50%-60% | 45%-80% |
| *MCP* single | 0%-6% | 70%-90% | 6%-38% | <20% |
| *MCP* combined1 | 30%-40% | 50% | 50% | 50%-60% |
| *C3* | 60% | 50% | 75% | 40%-70% |
| *CFB* | 50% | 3/3 | 75% | 100% |
| *THBD* | 50% | 30% | 54% | ? |
| *Anti-FH* | 30%-40% | 40%-60% | 35%-60% | Depends on antibody titers |

1Combined with *CFH* or *CFI* or *C3* mutations. Adapted from: Goodship *et al*[58]. *CFB:* Complement factor B gene; *CFH*: Complement factor H gene; *CFHR*: Complement factor H-related genes; *CFI*: Complement factor I gene; FH: Factor H protein; *THBD*: Thrombomodulin gene.

## Table 5 Eculizumab dosing in atypical hemolytic uremic syndrome based on dosing goal, 1 additional monitoring may be required during intercurrent events (*e.g*., infection, surgery, vaccination) to detect unblocked complement activity

|  |  |
| --- | --- |
| Minimal dose | Desire to continue dosing with the minimal dose required to achieve a pre-identified level of complement blockade 1  Dose reduction or interval extension  Goal CH50 < 10% (recommended)  Goal AH50 < 10% (recommended)  Goal eculizumab trough > 100 µg/mL |
| Discontinuation | Desire to discontinue complement blockade: No consensus exists regarding tapering of dose |

## Adapted from: Goodship *et al*[58]. AH50: Alternative pathway hemolytic activity; CH50: Total complement activity.

## Table 6 Monitoring eculizumab therapy

|  |  |
| --- | --- |
| Description | |
| CH50 (total complement activity) | Measures the combined activity of all of the complement pathways  Tests the functional capability of serum complement components to lyse 50% of sheep erythrocytes in a reaction mixture  Low in congenital complement deficiency (C1-8) or during complement blockade  Normal range is assay dependent  Recommended goal during therapeutic complement blockade:< 10% of normal |
| AH50 (alternative pathway hemolytic activity) | Measures combined activity of alternative and terminal complement pathways  Tests the functional capability of alternate or terminal pathway complement components to lyse 50% of rabbit erythrocytes in a Mg2+-EGTA buffer  Will be low in congenital C3, FI, FB, properdin, FH, and FD deficiencies or during terminal complement blockade  Normal range is assay dependent  Recommended goal during complement blockade:< 10% of normal |
| Eculizumab trough | May be a free or bound level  ELISA: Using C5 coated plates, patient sera, and an anti-human IgG detection system  Not affected by complement deficiencies.  Recommended trough level during complement blockade:50-100 μg/mL |
| Alternative assays | The following assays are under investigation (or awaiting to be replicated in different laboratories)[83] as a means to monitor therapeutic complement blockade  Free C5  *In vitro* human microvascular endothelial cell test  sC5b -9 (also referred to as sMAC and TCC) may remain detectable in aHUS patients in remission and therefore is not recommended as a monitoring tool |

Adapted from: Goodship *et al*[58]. aHUS: Atypical hemolytic uremic syndrome; C3: Complement component 3; C5: Complement component 5; EGTA: Ethyleneglycol tetraacetic acid; ELISA: Enzyme-linked immunosorbent assay; FB: Complement factor B; FD: Complement factor D; FH: Complement factor H; FI: Complement factor I; sC5b-9: Soluble C5b-9; sMAC: Soluble membrane attack complex; TCC: Terminal complement complex.